Abstract:Conventional genetic approaches and computational strategies have converged on immune-inflammatory pathways as key events in the pathogenesis of late onset sporadic Alzheimer’s disease (LOAD). Mutations and/or differential expression of microglial specific receptors such as TREM2, CD33, and CR3 have been associated with strong increased risk for developing Alzheimer’s disease (AD). DAP12 (DNAX-activating protein 12)/TYROBP, a molecule localized to microglia, is a direct partner/adapter for TREM2, CD33, and CR3. We and others have previously shown that TYROBP expression is increased in AD patients and in mouse models. Moreover, missense mutations in the coding region of TYROBP have recently been identified in some AD patients. These lines of evidence, along with computational analysis of LOAD brain gene expression, point to DAP12/TYROBP as a potential hub or driver protein in the pathogenesis of AD. Using a comprehensive panel of biochemical, physiological, behavioral, and transcriptomic assays, we evaluated in a mouse model the role of TYROBP in early stage AD. We crossed an Alzheimer’s model mutant APP KM670/671NL /PSEN1 Δexon9 (APP/PSEN1) mouse model with Tyrobp −/− mice to generate AD model mice deficient or null for TYROBP (APP/PSEN1; Tyrobp +/− or APP/PSEN1; Tyrobp −/−). While we observed relatively minor effects of TYROBP deficiency on steady-state levels of amyloid-β peptides, there was an effect of Tyrobp deficiency on the morphology of amyloid deposits resembling that reported by others for Trem2 −/− mice. We identified modulatory effects of TYROBP deficiency on the level of phosphorylation of TAU that was accompanied by a reduction in the severity of neuritic dystrophy. TYROBP deficiency also altered the expression of several AD related genes, including Cd33. Electrophysiological abnormalities and learning behavior deficits associated with APP/PSEN1 transgenes were greatly attenuated on a Tyrobp-null background. Some modulatory effects of TYROBP on Alzheimer’s-related genes were only apparent on a background of mice with cerebral amyloidosis due to overexpression of mutant APP/PSEN1. These results suggest that reduction of TYROBP gene expression and/or protein levels could represent an immune-inflammatory therapeutic opportunity for modulating early stage LOAD, potentially leading to slowing or arresting the progression to full-blown clinical and pathological LOAD.

Additional File 3: of Integrated Biology Approach Reveals Molecular and Pathological Interactions among Alzheimer’s Aβ42, Tau, TREM2, and TYROBP in Drosophila Models

Additional File 4: of Integrated Biology Approach Reveals Molecular and Pathological Interactions among Alzheimer’s Aβ42, Tau, TREM2, and TYROBP in Drosophila Models

Integrated Biology Approach Reveals Molecular and Pathological Interactions among Alzheimer’s Aβ42, Tau, TREM2, and TYROBP in Drosophila Models

Transcriptome and proteome profiling reveals TREM2-dependent and -independent glial response and metabolic perturbation in an Alzheimer's mouse model

Unraveling the Molecular Dance: Insights into TREM2/DAP12 Complex Formation in Alzheimer's Disease through Molecular Dynamics Simulations

A Computational Approach in the Systematic Search of the Interaction Partners of Alternatively Spliced TREM2 Isoforms

Functional BRI2-TREM2 interactions in microglia: implications for Alzheimer’s and related dementias

Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer’s disease

Single Nucleus Transcriptome Data from Alzheimer's Disease Mouse Models Yield New Insight into Pathophysiology.

Elevated TREM2 Gene Dosage Reprograms Microglia Responsivity and Ameliorates Pathological Phenotypes in Alzheimer’s Disease Models

Gene expression and functional deficits underlie TREM2-knockout microglia responses in human models of Alzheimer’s disease

TREM2-independent oligodendrocyte, astrocyte, and T cell responses to tau and amyloid pathology in mouse models of Alzheimer disease

Understanding the binding mechanisms of Alzheimer risk factor TREM2 in lipid bilayer using multi-scale molecular dynamics simulations

Integrative Metabolomics and Whole Transcriptome Sequencing Reveal Role for TREM2 in Metabolism Homeostasis in Alzheimer's Disease

Additional File 3 of the Fusiform Gyrus Exhibits an Epigenetic Signature for Alzheimer’s Disease

A systematic review of the role of TREM2 in Alzheimer's disease

Whole organism snRNA-seq reveals systemic peripheral changes in Alzheimer's Disease fly models

Additional File 8 of the Fusiform Gyrus Exhibits an Epigenetic Signature for Alzheimer’s Disease

Alzheimer’s disease modification mediated by bone marrow-derived macrophages via a TREM2-independent pathway in mouse model of amyloidosis

Deficiency of TYROBP, an Adapter Protein for TREM2 and CR3 Receptors, is Neuroprotective in a Mouse Model of Early Alzheimer’s Pathology

Dissecting The Pathological Effects Of Human A Beta 40 And A Beta 42 In Drosophila: A Potential Model For Alzheimer'S Disease